**Name of Journal:** *World Journal of Radiology*

**Manuscript NO:** 82467

**Manuscript Type:** MINIREVIEWS

**Future of prostate imaging - artificial intelligence in assessing prostatic magnetic resonance imaging**

Chervenkov L *et al*. AI in prostate imaging

Lyubomir Chervenkov, Nikolay Sirakov, Gancho Kostov, Tsvetelina Velikova, George Hadjidekov

**Lyubomir Chervenkov,** Department of Diagnostic Imaging, Medical University Plovdiv, Plovdiv 4000, Bulgaria

**Lyubomir Chervenkov,** Research Complex for Translational Neuroscience, Medical University of Plovdiv, Bul. Vasil Aprilov 15A, 4002 Plovdiv, Bulgaria

**Nikolay Sirakov,** Department of Diagnostic Imaging, Dental Allergology and Physiotherapy, Faculty of Dental Medicine, Medical University Plovdiv, Plovdiv 4000, Bulgaria

**Nikolay Sirakov,** Research Complex for Translational Neuroscience, Medical University of Plovdiv, Bul. Vasil Aprilov 15A, 4002 Plovdiv, Bulgaria

**Gancho Kostov,** Department of Special Surgery, Medical University Plovdiv, Plovdiv 4000, Bulgaria

**Tsvetelina Velikova,** Department of Clinical Immunology, University Hospital Lozenetz, Sofia 1407, Bulgaria

**Tsvetelina Velikova,** Department of Medical Faculty, Sofia University St. Kliment Ohridski, Sofia 1407, Bulgaria

**George Hadjidekov,** Department of Radiology, University Hospital Lozenetz, Sofia 1407, Bulgaria

**George Hadjidekov,** Department of Physics, Biophysics and Radiology, Medical Faculty, Sofia University St. Kliment Ohridski, Sofia 1407, Bulgaria

**Author contributions:** Chervenkov L, Velikova T, and Hadjidekov G proposed conceptualization; Chervenkov L; Sirakov N; Kostov G proposed Methodology; Chervenkov L proposed data Curation; Chervenkov L proposed Original Draft Preparation; Velikova, T and Hadjidekov G review and editing; and all authors revised and approved the final version of the manuscript, and approved the final version of the paper prior to submission.

**Corresponding author: George Hadjidekov, MD, PhD, Associate Professor,** Department of Radiology, University Hospital Lozenetz, 1 Kozyak street, Sofia 1407, Bulgaria. jordiman76@yahoo.com

**Received:** December 19, 2022

**Revised:** March 21, 2023

**Accepted:** April 10, 2023

**Published online:**

**Abstract**

Prostate cancer is one of the most common cancers in men and one of the leading causes of death. In recent years, with the advent of multiparametric magnetic resonance, the diagnostic approach of the disease has significantly improved, but certain limitations have also been discovered. The diagnosis of prostate carcinoma requires a lot of experience in the field, and yet the lesions are sometimes difficult to detect. Artificial intelligence (AI) has entered radiology in recent years, with new software solutions being offered in the field of prostate diagnostics. Through AI, precise mapping of the prostate is possible, which greatly improves accurate biopsy. With AI, certain suspicious lesions can be attributed to a given group according to the prostate imaging-reporting and data system classification. AI allows combining the data obtained from the clinical examination, the prostate-specific antigen levels, the result of the magnetic resonance imaging, the biopsy, and in this way new regularities can be found, which at the moment remain hidden. The introduction of AI is an inevitable process in the future, which will significantly expand the possibilities of diagnosis and treatment of prostate cancer.

**Key Words:** Artificial intelligence, Deep learning, Machine learning, Multiparametric magnetic resonance imaging, Prostate cancer, Quantitative imaging

Chervenkov L, Sirakov N, Kostov G, Velikova T, Hadjidekov G. Future of prostate imaging - artificial intelligence in assessing prostatic magnetic resonance imaging. *World J Radiol* 2023; In press

**Core Tip:** There are currently enough studies showing the possible benefits of using artificial intelligence in prostate cancer diagnosis. In addition, there are various software products to assist the radiologist in diagnosis in this field, created by leading companies. However, a new approach is needed in diagnosing prostate carcinoma due to the complexity of the disease.

**INTRODUCTION**

Prostate cancer is one of the leading causes of death from oncological diseases, and it ranks second in men. Despite the high frequency of the disease, a screening program has not yet been presented, and specialists in the field rely on rectal examination and prostate-specific antigen (PSA) testing. If a finding is detected, a transrectal ultrasound (TRUS) biopsy is performed[[1](#_ENREF_1" \o "Ferlay, 2019 #28)]. Prostate carcinoma is classified as clinically significant and non-significant, with the considerable carcinoma requiring surgical treatment due to the possibility of metastasis and the non-significant being followed up[[2-4](#_ENREF_2" \o "Fenton, 2018 #29)].

Multiparametric magnetic resonance imaging (mpMRI) is gaining ground as a primary method for prostate cancer diagnosis. However, the study creates certain difficulties and requires a profound knowledge of the field and serious experience with magnetic resonance imaging[[1-3](#_ENREF_1),[5](#_ENREF_5)]. The presentation of the prostate imaging-reporting and data system (PI-RADS) 2.1 system describes the findings detectable in prostate carcinoma, which aims to standardize the diagnosis of carcinoma[[6-8](#_ENREF_6" \o "Rosenkrantz, 2017 #42)].

mp-MRI has opened up new opportunities for PCa detection and diagnosis. It is specifically recommended for patients with elevated PSA levels but with negative biopsy results and biopsy naïve patients who are being monitored for PCa due to risk factors. In addition, mp-MRI is considered a safer alternative to TRUS biopsy, reducing the rate of post-biopsy complications[[4](#_ENREF_4" \o "Doykov, 2022 #67)].

Three-dimensional images of the prostate gland, including high-resolution T2-weighted, diffusion weighted imaging (DWI), and dynamic contrast-enhanced (DCE) images are obtained using mp-MRI (Figure 1).

The results are combined to determine the level of risk for clinically significant cancer, following the PI-RADS, whose most recent version from 2019 is characterized by improved sensitivity and specificity[[4](#_ENREF_4" \o "Doykov, 2022 #67)].

American and European guidelines differ from each other according to the exact appropriate time of biopsy[[9](#_ENREF_9" \o "Schoots, 2020 #47)]. Gleason staging has proven to be an accurate method, but it also has significant limitations in diagnosis and quantification. For example, there is an underestimation of tumor size with the PI-RADS system, especially in patients with a low PI-RADS score[[10](#_ENREF_10" \o "Pooli, 2021 #48)]. In addition, the heterogeneity of prostate carcinoma, the limitation of mpMRI, and possible biopsy errors sometimes lead to inconsistencies in the overall assessment of the patient's condition.

Currently, the detection of prostate carcinoma depends to a large extent on the experience of the radiologist, and in some cases even experienced radiologists find it difficult to detect the carcinoma or the detected lesions are difficult to classify by PI-RADS. In addition, in many cases, due to the hypertrophy of the prostate in adult patients, it is impossible to accurately localize the lesion and, accordingly, it is difficult to perform an accurate biopsy. It is also necessary to unify the description of a given lesion in relation to generally accepted templates. All these limitations can be overcome thanks to the development of new modern software technologies based on artificial intelligence (AI)[[11](#_ENREF_11" \o "Aggarwal, 2022 #69)].

***Challenges in assessing prostatic MRI***

The prostate cancer detection process has its weaknesses at present. Prostate carcinoma is often confused with prostatitis, benign nodules, or hemorrhagic nodules, especially in the transitional zone. This often necessitates unnecessary biopsies[[12](#_ENREF_12" \o "Loeb, 2013 #49)].

Another common mistake is the wrongly assessed tumor, leading to an inaccurate biopsy and a false negative result. Another possible error is in the mechanism of producing the pathological consequence, as well as wrong evaluation by the pathologist, who may miss or wrongly stage a carcinoma[[13](#_ENREF_13" \o "Etzioni, 2002 #50)].

AI is applied to various diseases in the field of imaging diagnostics and pathology, most often to increase efficiency in evaluating results. Especially in mpMRI, different AI solutions are used, which allow accurate segmentation of the prostate, as well as an accurate characterization of tumors[[14](#_ENREF_14" \o "Cuocolo, 2020 #51)]. In the field of pathology, an improvement in diagnostics has also been observed. Radiological-pathological correlation is required, increasing the need for AI, especially in combination with biomarker data. A mechanism is needed to support the analysis of patients in multidisciplinary teams – radiologists, pathologists, and urologists. Incorporating AI into disease diagnosis would improve discovering of hidden relationships between different biomarkers[[15](#_ENREF_15" \o "Goldenberg, 2019 #52),[16](#_ENREF_16)].

***AI in medicine***

AI is a computer system that performs actions similar to human intelligence. AI developed rapidly in Radiology in recent years due to the ability of AI to automatically extract information. Machine learning is an algorithm that is trained for specific tasks without human intervention, which means that computers can be trained from certain examinations that are previously described by the radiologist. As more research accumulates, the effectiveness of the software increases, and after human validation, calibration is performed, resulting in better sensitivity and specificity. A subtype of machine learning is convolutional neural networks, where different systems interact with each other[[17](#_ENREF_17" \o "Park, 2018 #54)]. Namely, this type of system is the most frequently used in the development of AI[[18](#_ENREF_18" \o "Yilmaz, 2022 #1)].

AI can improve the detection, characterization, staging and participation in adequately treating prostate carcinoma. Accurate prostate segmentation is particularly important when performing mpMRI, which is relatively conditional on the perceptions of individual specialists. AI can be involved in the primary detection and staging of lesions relative to the PI-RADS system. A study by Cuocolo *et al*[14] from 2021 shows a similar characterization of human *vs* AI findings. In addition, AI can optimize the exact site for biopsy, as well as create a three-dimensional model to accurately represent the location of the tumor and its relationship to neighboring organs, improving preoperative preparation.

Publications from recent years have shown regularity between the findings in T2, the changes in DWI and the density of tissue composition, allowing the creation of radiopathological maps[[19-21](#_ENREF_19" \o "McGarry, 2018 #55)].

AI has already been proven important in some other fields in medicine. Machine learning has been used in patients with appendicitis, and its role as tool to predict wether the disease is acute ot subacute. The AI showed 83.75%, precision of 84.11%, sensitivity of 81.08%, and specificity of 81.01%[[22](#_ENREF_22" \o "Mijwil, 2022 #2)]. The growing role of the precision medicine, the future improvements of machine learning and deep learning, the expansion of robotics and radiomics may play a key role for a robust and reproducible MRI-based prostatic diagnostics[[23](#_ENREF_23" \o "Hamm, 2020 #3)].

***AI challenges***

The greatest challenge to AI at the moment is the need for large volumes of data to be integrated into the systems, which requires a large volume of work time for radiologists with expertise in prostate imaging. Another challenge is that the collected data come from different MRIs from different manufacturers with varying field strengths, and the studies were performed using other protocols. This means that studies should be grouped into different groups. A study by Gaur *et al*[24] have showed reduction of the time of interpretation of studies with the help of AI is possible. The sensitivity also improved from 78% to 83.8%, especially in radiologists with less experience in the field[[24](#_ENREF_24" \o "Gaur, 2018 #60)].

***Current AI products available***

The diagnosis of prostate carcinoma involves initial detection and accurate classification of the finding, and it is to these processes that the forces of software companies are directed. AI systems are "trained" to detect cancer by inputting lots of data from leading experts. Several groups are reporting various AI models for prostate segmentation, intraprostatic lesion detection and classification tasks with auspicious results[[25](#_ENREF_25" \o "Belue, 2022 #7)].

Improvements are being sought in the detection of prostate carcinomas that are invisible to human perception, thereby increasing early diagnosis[[26-29](#_ENREF_26" \o "Winkel, 2020 #10)]. In Table 1, current AI products in the prostate field are demonstrated[[30](#_ENREF_30" \o "Greer, 2019 #15)].

"AI-Rad companion prostate MR" by Siemens aids fusion between MRI and ultrasound. Performing an ultrasound-guided biopsy alone carries risks such as hemorrhage, infection, and abscessation. Furthermore, the procedure may not provide an answer to the presence of carcinoma in the given patient if performed soley, without previous examination. At the same time, performing an mpMRI scan cannot give a histological diagnosis to the patient. The modern model of prostate carcinoma diagnosis includes an ultrasound examination in combination with a previously performed magnetic resonance scan. The lesions found on the magnetic resonance scan are described by a radiologist, after which the images are superimposed on the ultrasound machine and a fusion between the two methods is achieved. AI in this case assists the biopsy by applying automated segmentation of the prostate, thus saving time and increasing the accuracy of the biopsy. The collaboration between the urologist and the radiologist is improved, as it allows for additional targeting of the lesions detected on the magnetic resonance[[31](#_ENREF_31" \o "Strohm, 2020 #61)].

Another Siemens product is the Siemens Healthineers Prostate MR, which is available on the syngo.via workstation and is an AI that supports the evaluation of the images obtained during a multiparametric scan. Analysis time needed for the AI is extremely short – between 3 and 10 s. Prostate MR supports the primary detection and classification of findings, and offers description according to pre-entered standardized report templates. The use of this type of software is extremely valuable for training radiologists without experience in prostate diagnostics. With the help of the software, a reduction of false positive results was achieved[[32](#_ENREF_32" \o "Yu, 2020 #70)].

With the advent of multiparametric resonance, the amount of examinations performed has increased significantly. Radiologists today have to interpret multiple magnetic resonance imaging scans of the prostate, but this requires great expertise in this challenging field. New guidelines from the European Association of Urology and the American Association of Radiology suggest that an MRI be performed before any biopsy is performed, and currently the number of biopsies in the United States and Europe alone is over 3 million[[33](#_ENREF_33" \o "Mottet, 2021 #16)]. Eventual involvement of AI in the interpretation algorithm may improve the detection rate, accurate localization and risk stratification of patients with suspected prostate cancer. "Quantib® Prostate" offers fast and automated segmentation of the prostate and detection of findings on the most used multiparametric MRI sequences - T2, ADC, DWI, DCE. The software offers assistance in the PI-RADS classification of a discovery. Finally, with the help of the software, a standardized report can be written based on pre-created templates, thus saving time and improving the quality of the report.

The DCE perfusin software identifies tumors according to their vessel characteristics. The Pharmacokinetic model used in "Quantib® Prostate" helps detect neoplasms and quantifies tumor neoangiogenesis to stage cancer aggressiveness. This suite supports the characterization of tumoral processes in the early detection, diagnosis, treatment response evaluation and follow-up of patients with cancer. The software assesses the characteristics of the tissues, obtains T2 mapping and depicts the changes according to the segmentation. The information obtained allows the assessment and monitoring of solid tumors, such as prostate, rectal, and liver cancer[[31](#_ENREF_31" \o "Strohm, 2020 #61)].

"JPC-01K" is a neural network-based software used to characterize tumors on mp-MRI. This software aims to reduce the time needed to evaluate the prostate examination and assist in the description of findings by providing quantitative analysis. It also aims to overcome the difficulties in image analysis, which is largely dependent on the radiologist and his qualifications and experience. The system uses multiparametric MR images, T2, DWI, and DCE, as input and visualizes the location of prostate cancer and its probability. According to a study carried out in one center, the accuracy of the method was observed to be 99.65% with a time required for analysis of only 2 min. The AI at this manufacturer undergoes constant improvement through the addition of new data from leading experts.

"Prostate Intelligence™" is software that allows prostate tumor detection on MRI images. It is intended to augment a radiologist's interpretation of prostate MRI by providing a risk score, prostate segmentation and aiding lesion identification and segmentation. The processing time for this software is between 1 and 10 s. DWI by Quibim calculates the ADC coefficient. The suite provides information on the cellular and microstructural organization of tissues and highlights the relationship between pathological changes and the diffusion of water molecules. In addition, this suite aims to characterize tumoral processes to support early detection, diagnosis, treatment response evaluation and follow-up of patients.

DWI by Quibim is used to analyze the microstructure changes according to intra-voxel incoherent motion. The tool allows the differentiation of pure diffusion changes due to variations in the vascular component and offers additional information complementary to conventional ADC results. This suite aims to characterize tumoral processes to support early detection, diagnosis, treatment response evaluation and follow-up of patients[[31](#_ENREF_31" \o "Strohm, 2020 #61)].

For timely detection, accurate diagnosis and proper treatment of the patient, we offer the following algorithm presented in Figure 2.

***Opportunities***

Creating teams of radiologists and pathologists to jointly decide on the final outcome of patients with prostatic carcinoma would create a more efficient approach to treatment. With the help of AI, specialists from both fields can join forces, especially when making decisions about suspicious lesions classified as PI-RADS 3. It is possible to bring together in one system all critical components - disease history, PSA levels, imaging studies, genetic tests, laboratory tests, previous tests, histological results and treatment performed. AI can provide the ability to analyze all these components and compare them to databases for risk stratification and better predictability[[34](#_ENREF_34),[35](#_ENREF_35)].

***PET - CT at prostate cancer***

In prostate cancer, unlike most other carcinomas, the use of 18F-FDG in positron emission tomography/computedtomography (PET/CT) is limited due to low or missing glucose consumption by typical prostate carcinoma. This requires the use of specific targeting. Until recently, cholin markers were promising markers, but this radioactive indicator, originally used for re-staging after biochemical relapse and staging of high -risk patients, is practically abandoned due to its low sensitivity. Other markers such as 11C-acetate, 18F-oorocyclobutan-1-carboxylic acid and 18F -uciclovire have been tested without justifying expectations, presenting the same characteristics with choline. Prostate-specific membrane antigen (PSMA) currently dominates all other markers in PET scans of prostate carcinoma. PSMA, also known as glutamate carboxypeptidase II, is a transmembran glycoprotein, highly expressed in prostate cancer cells. PSMA expression tends to increase as Gleason increases. So far, several 68GA ligand has been designed to target PSMA, *e.g.* PSMA-11 (known as Hbed-Cc or Hbed-PSMA), PSMA-I & T and PSMA-617. Therefore, a 68GE/68GA generator with T1/2 of 271 days is widely used (Figure 3). However, in objects with cyclotron access PSMA-1007 looks like a big breakthrough as it shows an advantage over 68GA marked PSMA markers. Multiple studies show that PSMA PET/CT with PSMA has a moderate sensitivity, but a very high specificity of detecting metastases in lymph nodes and other organs. If the primary prostate cancer shows PSMA expression, the PSMA+ and PSMA- find will be characterized as a secondary lesion or will be treated accordingly as a minor/benign lesion in the fragment of imaging technique with high negative prognostic value. Due to the high cost of PSMA studies, a good selection of patients suitable for examination is required. MpMRI is superior for local assessment of the disease, and PSMA PET/MRI has advantage in whole body scanning. In addition to the benefits arising from PSMA PET/CT, several restrictions are noted for patients suffering from prostate carcinoma. PET cameras are not always available and are missing in some of the nuclear medicine departments, especially in the remote regions for various reasons. PSMA also have to be included in international quidelines. Another important point is to clarify its role in monitoring of the disease. PSMA PET/CT showed indisputable results in the diagnosis of prostate cancer. The method outperforms diagnostics based solely on PSA, CT and TRUS biopsy[[36-40](#_ENREF_36" \o "Hahn, 1997 #17)].

Currently, only Pylarify AI™ is legalized software for support in PSMA PET/CT examinations, by quantitative and accurate reporting of the studies. The AI software allows autamatical analisis of the CT examination, allowing targeting of the hotspots[[41](#_ENREF_41),[42](#_ENREF_42)].

**CONCLUSION**

The increased incidence of prostate cancer in recent years and the improvement of magnetic resonance imaging have led to an increase in the number of the performed examinatons. The larger volume of data combined with the insufficient number or insufficiently trained personnel creates difficulties in the diagnosis of the disease. AI is a powerful modern tool that offers time reduction, improvement in the quality and accuracy of interpretation of the prostatic carcinoma, according to the unified PI-RADS system. AI in the field of prostate imaging may revolutionize the approach to prostate cancer patients. However, it is necessary to go a long way to calibrate the individual components of the new software solutions and carry out many recent studies in this area.

**ACKNOWLEDGEMENTS**

The European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, project № BG-RRP-2.004-0008-C01.

**REFERENCES**

1 **Ferlay J**, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019; **144**: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]

2 **Fenton JJ**, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 2018; **319**: 1914-1931 [PMID: 29801018 DOI: 10.1001/jama.2018.3712]

3 **Hayes JH**, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. *JAMA* 2014; **311**: 1143-1149 [PMID: 24643604 DOI: 10.1001/jama.2014.2085]

4 **Doykov M,** Chervenkov, L., Tsvetkova-Trichkova, S., Doykova, K., Georgiev, A. Assessment of the Utility of Multiparametric Magnetic Resonance Imaging for Initial Detection of Prostate Cancer. *Macedonian Journal of Medical Sciences* 2022; **10**: 1840-1845 [DOI: 10.3889/oamjms.2022.10401]

5 **Barbieri CE**, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T, Rubin MA. The mutational landscape of prostate cancer. *Eur Urol* 2013; **64**: 567-576 [PMID: 23759327 DOI: 10.1016/j.eururo.2013.05.029]

6 **Rosenkrantz AB**, Ayoola A, Hoffman D, Khasgiwala A, Prabhu V, Smereka P, Somberg M, Taneja SS. The Learning Curve in Prostate MRI Interpretation: Self-Directed Learning Versus Continual Reader Feedback. *AJR Am J Roentgenol* 2017; **208**: W92-W100 [PMID: 28026201 DOI: 10.2214/AJR.16.16876]

7 **Turkbey B**, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. *Eur Urol* 2019; **76**: 340-351 [PMID: 30898406 DOI: 10.1016/j.eururo.2019.02.033]

8 **Georgiev A**, Chervenkov L, Doykov M, Doykova K, Uchikov P, Tsvetkova S. Surveillance Value of Apparent Diffusion Coefficient Maps: Multiparametric MRI in Active Surveillance of Prostate Cancer. *Cancers (Basel)* 2023; **15** [PMID: 36831471 DOI: 10.3390/cancers15041128]

9 **Schoots IG**, Padhani AR. Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis. *Abdom Radiol (NY)* 2020; **45**: 4012-4022 [PMID: 32356003 DOI: 10.1007/s00261-020-02547-x]

10 **Pooli A**, Johnson DC, Shirk J, Markovic D, Sadun TY, Sisk AE Jr, Mohammadian Bajgiran A, Afshari Mirak S, Felker ER, Hughes AK, Raman SS, Reiter RE. Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. *J Urol* 2021; **205**: 444-451 [PMID: 33026934 DOI: 10.1097/JU.0000000000001389]

11 **Aggarwal K. Has the Future Started? The Current Growth of Artificial Intelligence,** Machine Learning, and Deep Learning. *Iraqi Journal for Computer Science and Mathematics* 2022; **3**: 115-123 [DOI: 10.52866/ijcsm.2022.01.01.013]

12 **Loeb S**, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y. Systematic review of complications of prostate biopsy. *Eur Urol* 2013; **64**: 876-892 [PMID: 23787356 DOI: 10.1016/j.eururo.2013.05.049]

13 **Etzioni R**, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. *J Natl Cancer Inst* 2002; **94**: 981-990 [PMID: 12096083 DOI: 10.1093/jnci/94.13.981]

14 **Cuocolo R**, Cipullo MB, Stanzione A, Romeo V, Green R, Cantoni V, Ponsiglione A, Ugga L, Imbriaco M. Machine learning for the identification of clinically significant prostate cancer on MRI: a meta-analysis. *Eur Radiol* 2020; **30**: 6877-6887 [PMID: 32607629 DOI: 10.1007/s00330-020-07027-w]

15 **Goldenberg SL**, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. *Nat Rev Urol* 2019; **16**: 391-403 [PMID: 31092914 DOI: 10.1038/s41585-019-0193-3]

16 **Raciti P**, Sue J, Ceballos R, Godrich R, Kunz JD, Kapur S, Reuter V, Grady L, Kanan C, Klimstra DS, Fuchs TJ. Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsies. *Mod Pathol* 2020; **33**: 2058-2066 [PMID: 32393768 DOI: 10.1038/s41379-020-0551-y]

17 **Park SH**, Han K. Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction. *Radiology* 2018; **286**: 800-809 [PMID: 29309734 DOI: 10.1148/radiol.2017171920]

18 **Yilmaz EC**, Belue MJ, Turkbey B, Reinhold C, Choyke PL. A Brief Review of Artificial Intelligence in Genitourinary Oncological Imaging. *Can Assoc Radiol J* 2022: 8465371221135782 [PMID: 36515576 DOI: 10.1177/08465371221135782]

19 **McGarry SD**, Hurrell SL, Iczkowski KA, Hall W, Kaczmarowski AL, Banerjee A, Keuter T, Jacobsohn K, Bukowy JD, Nevalainen MT, Hohenwalter MD, See WA, LaViolette PS. Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer. *Int J Radiat Oncol Biol Phys* 2018; **101**: 1179-1187 [PMID: 29908785 DOI: 10.1016/j.ijrobp.2018.04.044]

20 **Chatterjee A**, Bourne RM, Wang S, Devaraj A, Gallan AJ, Antic T, Karczmar GS, Oto A. Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study. *Radiology* 2018; **287**: 864-873 [PMID: 29393821 DOI: 10.1148/radiol.2018171130]

21 **Chatterjee A**, Watson G, Myint E, Sved P, McEntee M, Bourne R. Changes in Epithelium, Stroma, and Lumen Space Correlate More Strongly with Gleason Pattern and Are Stronger Predictors of Prostate ADC Changes than Cellularity Metrics. *Radiology* 2015; **277**: 751-762 [PMID: 26110669 DOI: 10.1148/radiol.2015142414]

22 **Mijwil MM**, Aggarwal K. A diagnostic testing for people with appendicitis using machine learning techniques. *Multimed Tools Appl* 2022; **81**: 7011-7023 [PMID: 35095329 DOI: 10.1007/s11042-022-11939-8]

23 **Hamm CA**, Beetz NL, Savic LJ, Penzkofer T. [Artificial intelligence and radiomics in MRI-based prostate diagnostics]. *Radiologe* 2020; **60**: 48-55 [PMID: 31802148 DOI: 10.1007/s00117-019-00613-0]

24 **Gaur S**, Lay N, Harmon SA, Doddakashi S, Mehralivand S, Argun B, Barrett T, Bednarova S, Girometti R, Karaarslan E, Kural AR, Oto A, Purysko AS, Antic T, Magi-Galluzzi C, Saglican Y, Sioletic S, Warren AY, Bittencourt L, Fütterer JJ, Gupta RT, Kabakus I, Law YM, Margolis DJ, Shebel H, Westphalen AC, Wood BJ, Pinto PA, Shih JH, Choyke PL, Summers RM, Turkbey B. Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation. *Oncotarget* 2018; **9**: 33804-33817 [PMID: 30333911 DOI: 10.18632/oncotarget.26100]

25 **Belue MJ**, Turkbey B. Tasks for artificial intelligence in prostate MRI. *Eur Radiol Exp* 2022; **6**: 33 [PMID: 35908102 DOI: 10.1186/s41747-022-00287-9]

26 **Winkel DJ**, Wetterauer C, Matthias MO, Lou B, Shi B, Kamen A, Comaniciu D, Seifert HH, Rentsch CA, Boll DT. Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept. *Diagnostics (Basel)* 2020; **10** [PMID: 33202680 DOI: 10.3390/diagnostics10110951]

27 **Aldoj N**, Lukas S, Dewey M, Penzkofer T. Semi-automatic classification of prostate cancer on multi-parametric MR imaging using a multi-channel 3D convolutional neural network. *Eur Radiol* 2020; **30**: 1243-1253 [PMID: 31468158 DOI: 10.1007/s00330-019-06417-z]

28 **Mehralivand S**, Yang D, Harmon SA, Xu D, Xu Z, Roth H, Masoudi S, Sanford TH, Kesani D, Lay NS, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B. A Cascaded Deep Learning-Based Artificial Intelligence Algorithm for Automated Lesion Detection and Classification on Biparametric Prostate Magnetic Resonance Imaging. *Acad Radiol* 2022; **29**: 1159-1168 [PMID: 34598869 DOI: 10.1016/j.acra.2021.08.019]

29 **Winkel DJ**, Tong A, Lou B, Kamen A, Comaniciu D, Disselhorst JA, Rodríguez-Ruiz A, Huisman H, Szolar D, Shabunin I, Choi MH, Xing P, Penzkofer T, Grimm R, von Busch H, Boll DT. A Novel Deep Learning Based Computer-Aided Diagnosis System Improves the Accuracy and Efficiency of Radiologists in Reading Biparametric Magnetic Resonance Images of the Prostate: Results of a Multireader, Multicase Study. *Invest Radiol* 2021; **56**: 605-613 [PMID: 33787537 DOI: 10.1097/RLI.0000000000000780]

30 **Greer MD**, Shih JH, Lay N, Barrett T, Bittencourt L, Borofsky S, Kabakus I, Law YM, Marko J, Shebel H, Merino MJ, Wood BJ, Pinto PA, Summers RM, Choyke PL, Turkbey B. Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. *AJR Am J Roentgenol* 2019; **212**: 1197-1205 [PMID: 30917023 DOI: 10.2214/AJR.18.20536]

31 **Strohm L**, Hehakaya C, Ranschaert ER, Boon WPC, Moors EHM. Implementation of artificial intelligence (AI) applications in radiology: hindering and facilitating factors. *Eur Radiol* 2020; **30**: 5525-5532 [PMID: 32458173 DOI: 10.1007/s00330-020-06946-y]

32 Yu X. False Positive Reduction Using Multiscale Contextual Features for Prostate Cancer Detection in Multi-Parametric MRI Scans. *IEEE 17th International Symposium on Biomedical Imaging (ISBI)* 2020: 1355-1359 [DOI: 10.1109/ISBI45749.2020.9098338]

33 **Mottet N**, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol* 2021; **79**: 243-262 [PMID: 33172724 DOI: 10.1016/j.eururo.2020.09.042]

34 **van Wijk Y**, Halilaj I, van Limbergen E, Walsh S, Lutgens L, Lambin P, Vanneste BGL. Decision Support Systems in Prostate Cancer Treatment: An Overview. *Biomed Res Int* 2019; **2019**: 4961768 [PMID: 31281840 DOI: 10.1155/2019/4961768]

35 **Lee G**, Singanamalli A, Wang H, Feldman MD, Master SR, Shih NN, Spangler E, Rebbeck T, Tomaszewski JE, Madabhushi A. Supervised multi-view canonical correlation analysis (sMVCCA): integrating histologic and proteomic features for predicting recurrent prostate cancer. *IEEE Trans Med Imaging* 2015; **34**: 284-297 [PMID: 25203987 DOI: 10.1109/TMI.2014.2355175]

36 **Hahn P**, Smith IC, Leboldus L, Littman C, Somorjai RL, Bezabeh T. The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra. *Cancer Res* 1997; **57**: 3398-3401 [PMID: 9270004]

37 **Tsechelidis I**, Vrachimis A. PSMA PET in Imaging Prostate Cancer. *Front Oncol* 2022; **12**: 831429 [PMID: 35155262 DOI: 10.3389/fonc.2022.831429]

38 **Siva S**, Udovicich C, Tran B, Zargar H, Murphy DG, Hofman MS. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. *Nat Rev Urol* 2020; **17**: 107-118 [PMID: 31937920 DOI: 10.1038/s41585-019-0272-5]

39 **Zamboglou C**, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, Bronsert P, Koeber G, Schilling O, Ruf J, Werner M, Jilg CA, Baltas D, Mix M, Grosu AL. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. *Theranostics* 2019; **9**: 2595-2605 [PMID: 31131055 DOI: 10.7150/thno.32376]

40 **Nishino M**, Hayakawa K, Minami M, Yamamoto A, Ueda H, Takasu K. Primary retroperitoneal neoplasms: CT and MR imaging findings with anatomic and pathologic diagnostic clues. *Radiographics* 2003; **23**: 45-57 [PMID: 12533639 DOI: 10.1148/rg.231025037]

41 **Nickols N**, Anand A, Johnsson K, Brynolfsson J, Borreli P, Parikh N, Juarez J, Jafari L, Eiber M, Rettig M. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL Images of Veterans with Prostate Cancer. *J Nucl Med* 2022; **63**: 233-239 [PMID: 34049980 DOI: 10.2967/jnumed.120.261863]

42 **Johnsson K**, Brynolfsson J, Sahlstedt H, Nickols NG, Rettig M, Probst S, Morris MJ, Bjartell A, Eiber M, Anand A. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting. *Eur J Nucl Med Mol Imaging* 2022; **49**: 1041-1051 [PMID: 34463809 DOI: 10.1007/s00259-021-05497-8]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** European Society of Radiology ESR; Bulgarian Association of Radiology BAR; European Society of Uroradiology ESUR; European Society of Gastroabdominal Radiology ESGAR.

**Peer-review started:** December 19, 2022

**First decision:** February 20, 2023

**Article in press:**

**Specialty type:** Radiology, nuclear medicine and medical imaging

**Country/Territory of origin:** Bulgaria

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Konovalov AB, Russia; Lei Y, China; Mijwil MM, Iraq **S-Editor:** Liu XF **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Apical peripheral zone with a prostate imaging-reporting and data system 5 Lesion.** A and B: Axial and coronal T2WI shows homogeneous hypointense lesion in the anterior peripheral zone of the apex (PZ a); C: Postcontrast axial T1WI demonstrates pronounced enhancement of the lesion; D: Early dynamic contrast-enhanced image presents positive enhancement within the lesion and a wash-out signal intensity curve; and E: DWI and ADC diffusion restriction [DWI (b = 1000 s/mm2)] shows a marked hyperintense signal above the background, while ADC map image presents a lesion with hypointense signal below the background. T2WI: T2-weighted; DWI: Diffusion weighted imaging; ADC: Apparent diffusion coefficient.



**Figure 2 Prostate cancer diagnosis algorithm.**



**Figure 3 Images from a 68Ga PSMA PET-CT in a patient with prostate carcinoma shows the primary tumor and diffuse lymph nodal metastatic spread as well as multiple spinal metastases.** PSMA: Prostate-specific membrane antigen**;** PET/CT: Positron emission tomography/computedtomography.

**Table 1 Current artificial intelligence products are available in the prostate field**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Vendor** | **Product name** | **FDA approvement** | **CE approvement** | **Main features in prostate imaging** |
| Siemens Healthineers | AI-Rad Companion Prostate MR | Class II | Class IIb - MDR | Segmentation, volume assessment, lesion annotation, PSA density |
| Quantib | QUANTIB® Prostate | Class II | Class IIb - MDR | Volume assessment, PSA density, segmentation, PI-RADS scoring, report structure |
| Quibim | QP-Prostate | Class II | Class IIb - MDR | ADC, Ktrans, parametric maps obtainment, volume assessment, segmentation, report structure |
|
| Quibim | Perfusion pharmacokinetics modeling | 　 | Class IIa - MDD | Ktrans map, volume assessment, contrast enhancement assistance |
| Quibim | Texture analysis | 　 | Class IIa - MDD | Quantification, radiomics, imaging biomarker discovery |
| Quibim | T2 mapping (relaxometry) | 　 | Class IIa - MDD | T2 values, T2 histogram |
| Siemens Healthineers | Prostate MR on syngo *via* | 　 | Class IIa - MDD | Segmentation, volume assessment, lesion assessment, PI-RADS scoring |
|
| JLK Inc. | JPC-01K | 　 | Class I - MDD | Lesion detection |
| Lucida medical | Prostate Intelligence™ | 　 | Class I - MDD | Segmentation, lesion characterization, PI-RADS scoring, report structure |
| Quibim | DWI - ADC | 　 | Class IIa - MDD | Volume assessment, ADC support, Histogram |
| Quibim | DWI - IVIM | 　 | Class IIa - MDD | ADC support, multiparametric maps, perfusion assessment |

FDA: Food and Drug Administration; CE: Single Market in the European Economic Area (EEA); AI: Artificial intelligence; MR: Magnetic resonance; MDR: Medical Device Regulation; MDD: Medical Devices Directive; PSA: Prostate-specific antigen; PI-RADS: Prostate imaging-reporting and data system; JPC-01K: An artificial intelligence-based prostate cancer detection solution; DWI: Diffusion weighted imaging; ADC: Apparent diffusion coefficient; IVIM: Intravoxel Incoherent Motion.